Finance

Lists
Q3 2026 earnings • released • EPS beat +२१.१२% • Revenue beat +५.८०%
See results
WST:NYSE
West Pharmaceutical Services Inc
US$ ४१२.६२
-०.९७%
(-४.०५) 1D
US$ ४१२.६२
०.००% (०.००)
After hours
Closed: अक्टोबर ३०, १५:००:०७ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WST...
Open
US$ ४१९.०६
High
US$ ४२२.०८
Low
US$ ४०७.६७
Mkt. cap
२९.०४ अरब
Avg. vol.
६.३६ लाख
Volume
१०.६२ लाख
Dividend
०.२५%
Quarterly dividend
US$ ०.२६
Ex-dividend date
२०२६ जुलाई २९
P/E ratio
४६.२८
52-wk high
US$ ४३८.२७
52-wk low
US$ २२३.८३
EPS
US$ ८.९२
Beta
१.१३
Shares outstanding
७.०४ करोड
No. of employees
११ हजार
Open
US$ ४१९.०६
High
US$ ४२२.०८
Low
US$ ४०७.६७
Mkt. cap
२९.०४ अरब
Avg. vol.
६.३६ लाख
Volume
१०.६२ लाख
Dividend
०.२५%
Quarterly dividend
US$ ०.२६
Ex-dividend date
२०२६ जुलाई २९
P/E ratio
४६.२८
52-wk high
US$ ४३८.२७
52-wk low
US$ २२३.८३
EPS
US$ ८.९२
Beta
१.१३
Shares outstanding
७.०४ करोड
No. of employees
११ हजार
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
४ घण्टा पहिले
How Investors Are Reacting To West (WST) Earnings Beat
Yahoo Finance
Yahoo Finance
·
५ घण्टा पहिले
West Pharmaceutical Services (WST) Lifted Its Outlook, Is The Stock Fully Priced?
Yahoo! Finance Canada
Yahoo! Finance Canada
·
२ दिन पहिले
West Pharmaceutical Services, Inc. (WST) Seasonal Returns Chart - Yahoo Finance
GuruFocus
GuruFocus
·
३ दिन पहिले
West Pharmaceutical Services Inc (WST) (Q3 2026) Earnings Call H
Profile
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin. Wikipedia
About West Pharmaceutical Services Inc
CEOEric M. Green
Employees१०.८ हजार
Founded१९२३
HeadquartersWest Whiteland Township, पेन्सिलभेनिया, संयुक्त राज्य अमेरिका
Sector-
Websitewestpharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to WST in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for WST in the last 3 months.
Highest
Current US$ ४१२.६२
US$ ५००.०० (+२१.१८%)
Average
US$ ४७८.१७ (+१५.८९%)
Lowest
US$ ४००.०० (-३.०६%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brendan Smith
TD Cowen
Buy
Maintained
US$ ५००.००
+२१.२%
10/30/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
US$ ४८०.००
+१६.३%
10/30/2026
Unknown Analyst
UBS
Buy
Maintained
US$ ४९५.००
+२०%
10/30/2026
Joanne Wuensch
Citi
Buy
Reiterated
US$ ४९४.००
+१९.७%
10/30/2026
Luke Sergott
Barclays
Buy
Maintained
US$ ५००.००
+२१.२%
10/30/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Upgraded
US$ ४००.००
-३.१%
09/22/2026
Doug Schenkel
UBS
Buy
Maintained
US$ ४१५.००
+०.६%
09/09/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
US$ ४१०.००
-०.६%
07/24/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/23/2026
Curtis Moiles
Exane BNP Paribas
Buy
Initiated
US$ ४४७.००
+८.३%
07/13/2026
Paul Knight
KeyBanc
Buy
Maintained
US$ ३९०.००
-५.५%
07/02/2026
Michael Polark
Wolfe Research
Buy
Reiterated
US$ ३७५.००
-९.१%
06/01/2026
Patrick B Donnelly
Citi
Buy
Maintained
US$ ४००.००
-३.१%
04/24/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
-
-
04/23/2026
Dan Leonard
UBS
Buy
Maintained
US$ ३४०.००
-१७.६%
02/13/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
US$ ३१५.००
-२३.७%
02/13/2026
David Windley
Jefferies
Buy
Maintained
US$ २९५.००
-२८.५%
02/10/2026
Nico Chen
DBS
Buy
Maintained
US$ ३२०.००
-२२.४%
01/28/2026
Last report
२०२६ अक्टोबर २९
Fiscal period
Q3 2026
US$ २.६६ / US$ २.२०
+२१.१२%beat
Revenue / Est. (USD)
८७.४५ करोड / ८२.६५ करोड
+५.८०%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
८०.४६ करोड
८०.५० करोड
८४.४९ करोड
८७.२३ करोड
Cost of goods sold
५१.०३ करोड
५०.११ करोड
५४.८५ करोड
५४.३१ करोड
Cost of revenue
५१.०३ करोड
५०.११ करोड
५४.८५ करोड
५४.३१ करोड
Research and development expenses
१.७१ करोड
२.१८ करोड
१.५८ करोड
१.९७ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१०.११ करोड
१०.७५ करोड
९.९५ करोड
११.२० करोड
Operating expense
११.८५ करोड
१२.९७ करोड
११.३१ करोड
१३.३२ करोड
Total operating expenses
६२.८८ करोड
६३.०८ करोड
६६.१६ करोड
६७.६३ करोड
Operating income
१७.५८ करोड
१७.४२ करोड
१८.३३ करोड
१९.६० करोड
Other non operating income
-२.०० लाख
६.०० लाख
-२.०० लाख
-२.०० लाख
EBT including unusual items
१७.४० करोड
१६.५४ करोड
१८.३५ करोड
१८.६२ करोड
EBT excluding unusual items
१७.९५ करोड
१८.१२ करोड
१८.८६ करोड
२०.१२ करोड
Income tax expense
३.४० करोड
३.३३ करोड
४.४७ करोड
३.२२ करोड
Effective tax rate
१९.५४%
२०.१३%
२४.३६%
१७.२९%
Other operating expenses
३.०० लाख
४.०० लाख
-२२.०० लाख
१५.०० लाख
Net income
१४.०० करोड
१३.२१ करोड
१३.८८ करोड
१५.४० करोड
Net profit margin
१७.४०%
१६.४१%
१६.४३%
१७.६५%
Earnings per share
१.९६
२.०४
२.१३
२.३७
Interest and investment income
४७.०० लाख
५३.०० लाख
५१.०० लाख
३८.०० लाख
Interest expense
-२.०० लाख
-
-१९.०० लाख
-२६.०० लाख
Net interest expenses
४५.०० लाख
५३.०० लाख
३२.०० लाख
१२.०० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
२१.८८ करोड
२२.१२ करोड
२२.८५ करोड
२४.२२ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू